B C de Jong
Overview
Explore the profile of B C de Jong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cuella-Martin I, Runyambo D, De Bock S, Diels M, Niyompano H, Hakizayezu F, et al.
J Clin Microbiol
. 2025 Mar;
:e0180624.
PMID: 40029092
Importance: This paper addresses the critical need for faster direct drug-susceptibility testing (DST) on sputum, especially for bedaquiline (BDQ), which is a key drug in treating drug-resistant TB. Currently, there...
2.
Snobre J, Meehan C, Mulders W, Rigouts L, Buyl R, de Jong B, et al.
Antimicrob Agents Chemother
. 2024 Oct;
68(12):e0085424.
PMID: 39445816
Bedaquiline (BDQ) is crucial for the treatment of rifampicin-resistant tuberculosis, yet resistance threatens its effectiveness, mainly linked to mutations in the () gene. While frameshift mutations are thought to produce...
3.
Patil S, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A, et al.
Trials
. 2023 Dec;
24(1):773.
PMID: 38037119
Background: Treatment for fluoroquinolone-resistant multidrug-resistant/rifampicin-resistant tuberculosis (pre-XDR TB) often lasts longer than treatment for less resistant strains, yields worse efficacy results, and causes substantial toxicity. The newer anti-tuberculosis drugs, bedaquiline...
4.
Snobre J, Villellas M, Coeck N, Mulders W, Tzfadia O, de Jong B, et al.
Sci Rep
. 2023 Jun;
13(1):10444.
PMID: 37369740
Drug-resistant tuberculosis is a serious global health threat. Bedaquiline (BDQ) is a relatively new core drug, targeting the respiratory chain in Mycobacterium tuberculosis (Mtb). While mutations in the BDQ target...
5.
Krausser L, Braet S, Benaamar Z, Van Dyck-Lippens M, de Jong B, Rigouts L
Diagn Microbiol Infect Dis
. 2023 Mar;
106(1):115905.
PMID: 36905764
Efficient inactivation of clinical samples containing mycobacteria is crucial for biosafety during shipment and handling. When stored in RNAlater, Mycobacterium tuberculosis H37Ra remains viable, and our results suggest that at...
6.
Akkerman O, Duarte R, Tiberi S, Schaaf H, Lange C, Alffenaar J, et al.
Int J Tuberc Lung Dis
. 2022 Jun;
26(7):592-604.
PMID: 35768923
The aim of these clinical standards is to provide guidance on 'best practice´ for diagnosis, treatment and management of drug-susceptible pulmonary TB (PTB). A panel of 54 global experts in...
7.
Ejo M, Van Deun A, Nunn A, Meredith S, Ahmed S, Dalai D, et al.
Int J Tuberc Lung Dis
. 2021 Oct;
25(10):839-845.
PMID: 34615581
To assess the performance of the GenoType MTBDR v1, a line-probe assay (LPA), to exclude baseline resistance to fluoroquinolones (FQs) and second-line injectables (SLIs) in the Standard Treatment Regimen of...
8.
Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, et al.
Trials
. 2021 Sep;
22(1):651.
PMID: 34563240
Background: Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who...
9.
Van Deun A, Piubello A, Lynen L, de Jong B, Decroo T
Int J Tuberc Lung Dis
. 2021 Mar;
25(4):327-328.
PMID: 33762079
No abstract available.
10.
Ardizzoni E, Ariza E, Mulengwa D, Mpala Q, de La Tour R, Maphalala G, et al.
Antimicrob Agents Chemother
. 2021 Mar;
65(6).
PMID: 33722892
Xpert MTB/RIF rapidly detects resistance to rifampicin (RR); however, this test misses I491F-RR conferring mutation, common in southern Africa. In addition, Xpert MTB/RIF does not distinguish between viable and dead...